These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16268434)

  • 1. The respective roles of controlled clinical trials and cohort monitoring studies in the pre- and postmarketing assessment of drugs.
    Vray M; Hamelin B; Jaillon P;
    Therapie; 2005; 60(4):339-44, 345-9. PubMed ID: 16268434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Discussion on methods of sample size estimation in conducting clinical reevaluation of postmarketing Chinese medicine].
    Tian F; Fu Y; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Apr; 36(8):1097-102. PubMed ID: 21809593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmarketing surveillance versus clinical trials: which benefits the patient?
    Lawson DH
    Cardiology; 1994; 85 Suppl 1():18-23. PubMed ID: 7743530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of almotriptan in postmarketing surveillance studies.
    Pascual J
    Eur Neurol; 2005; 53 Suppl 1():34-40. PubMed ID: 15920336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pathway to improved prospective observational post-authorization safety studies.
    Kiri VA
    Drug Saf; 2012 Sep; 35(9):711-24. PubMed ID: 22861669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.
    Shepshelovich D; Tibau A; Goldvaser H; Ocana A; Seruga B; Amir E
    Mayo Clin Proc; 2019 Jan; 94(1):74-83. PubMed ID: 30611457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmarketing evaluation of drugs. Actual efficacy, population exposed and impact on public health.
    Le Galès C; el Hasnaoui A; Goehrs JM
    Therapie; 2003; 58(3):209-19. PubMed ID: 14655316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postmarketing drug surveillance: an epidemiologic approach.
    Hennessy S
    Clin Ther; 1998; 20 Suppl C():C32-9. PubMed ID: 9915088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmarketing evaluations help determine contraceptive safety, efficacy.
    Netw Res Triangle Park N C; 1988; 9(2):1-2, 7. PubMed ID: 12280950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013-2017.
    Brown JP; Wing K; Evans SJ; Bhaskaran K; Smeeth L; Douglas IJ
    BMJ Open; 2019 Oct; 9(10):e028133. PubMed ID: 31662354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is pharmacoepidemiology? Definition, methods, interest and clinical applications.
    Montastruc JL; Benevent J; Montastruc F; Bagheri H; Despas F; Lapeyre-Mestre M; Sommet A
    Therapie; 2019 Apr; 74(2):169-174. PubMed ID: 30389102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving multiple sclerosis management and collecting safety information in the real world: the MSDS3D software approach.
    Haase R; Wunderlich M; Dillenseger A; Kern R; Akgün K; Ziemssen T
    Expert Opin Drug Saf; 2018 Apr; 17(4):369-378. PubMed ID: 29436244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of the Methods to Obtain Paediatric Drug Safety Information: Spontaneous Reporting and Healthcare Databases, Active Surveillance Programmes, Systematic Reviews and Meta-analyses.
    Gentili M; Pozzi M; Peeters G; Radice S; Carnovale C
    Curr Clin Pharmacol; 2018; 13(1):28-39. PubMed ID: 29412117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sources of Safety Data and Statistical Strategies for Design and Analysis: Real World Insights.
    Marchenko O; Russek-Cohen E; Levenson M; Zink RC; Krukas-Hampel MR; Jiang Q
    Ther Innov Regul Sci; 2018 Mar; 52(2):170-186. PubMed ID: 29714518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Essentials for starting a pediatric clinical study (4): Clinical pediatric safety planning based on preclinical toxicity studies and pediatric pharmacovigilance guidance.
    Sheth N
    J Toxicol Sci; 2009; 34 Suppl 2():SP327-9. PubMed ID: 19571487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trials and observational studies in the assessment of drug safety.
    Sawchik J; Hamdani J; Vanhaeverbeek M
    Rev Epidemiol Sante Publique; 2018 May; 66(3):217-225. PubMed ID: 29685700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAFETY PROFILE OF OCRIPLASMIN FOR SYMPTOMATIC VITREOMACULAR ADHESION: A Comprehensive Analysis of Premarketing and Postmarketing Experiences.
    Hahn P; Chung MM; Flynn HW; Huang SS; Kim JE; Mahmoud TH; Sadda SR; Dugel PU
    Retina; 2015 Jun; 35(6):1128-34. PubMed ID: 25635575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and follow-up of postmarketing studies of conditionally authorized medicines in the EU.
    Hoekman J; Klamer TT; Mantel-Teeuwisse AK; Leufkens HG; De Bruin ML
    Br J Clin Pharmacol; 2016 Jul; 82(1):213-26. PubMed ID: 26992001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tolerance and safety of tramadol use. Results of international studies and data from drug surveillance].
    Cossmann M; Kohnen C; Langford R; McCartney C
    Drugs; 1997; 53 Suppl 2():50-62. PubMed ID: 9190325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.